Free Testosterone: Which Tests to Order Alongside

Why free testosterone is not a standalone answer

Testosterone circulates mostly bound to sex hormone-binding globulin (SHBG) and albumin; the free fraction is small. A total result can therefore appear discordant with symptoms when SHBG is unusually high or low. The Endocrine Society guideline recommends diagnosing hypogonadism only in people who have compatible symptoms or signs and unequivocally, consistently low serum testosterone. It recommends a fasting morning total-testosterone measurement, confirmation with a repeat morning measurement, and a free-testosterone assessment when the total result is near the lower limit or a condition changes SHBG.

This sequencing is important because laboratory methods differ. Endotext's laboratory assessment explains why assay method and binding proteins matter in testosterone interpretation. Some direct analogue free-testosterone immunoassays are not interchangeable with equilibrium dialysis or a calculation based on total testosterone, SHBG, and albumin. The result should be interpreted using the method and reference interval on that laboratory report. A number copied from a social-media chart is not a substitute for the lab's own interval or clinical context.

Core tests to discuss with a clinician

Morning total testosterone

For an initial evaluation, total testosterone is the anchor test. MedlinePlus' testosterone test overview describes why the result needs clinical interpretation. Acute illness, poor sleep, heavy alcohol use, major calorie restriction, and some medicines can temporarily influence results. Testing in the morning and repeating an unexpectedly low result reduces the chance that a transient change becomes a lifelong label.

SHBG and albumin

SHBG helps explain why total and free testosterone may not point in the same direction. Obesity, diabetes, thyroid disease, liver disease, aging, some anticonvulsants, and estrogen-containing medicines can affect SHBG. The Endocrine Society's guideline resource describes when free-testosterone assessment can be useful. Albumin is commonly needed when a clinician uses a validated calculated free-testosterone method. These are interpretation tools, not proof that treatment is necessary.

LH and FSH after low testosterone is confirmed

Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) are used to distinguish a pattern consistent with primary testicular dysfunction from one suggesting a pituitary or hypothalamic cause. The Endocrine Society's patient overview describes the distinction in plain language. The appropriate next step depends on the whole pattern. Prolactin may be relevant when secondary hypogonadism is suspected, especially with very low testosterone or symptoms that point toward a pituitary condition. A clinician may decide that additional pituitary evaluation is needed rather than simply beginning testosterone.

Tests guided by the question, not a universal bundle

CBC/hematocrit, PSA discussion, fertility evaluation, estradiol, thyroid testing, iron studies, glucose testing, and liver tests may each be useful in particular circumstances. They are not all required for every person seeking a "testosterone panel." The FDA's testosterone safety information is a useful complement to individualized risk review. For example, hematocrit monitoring is central for people receiving testosterone therapy because erythrocytosis is a recognized treatment risk. Fertility plans deserve explicit discussion before treatment: exogenous testosterone can suppress sperm production.

What a careful interpretation looks like

A useful appointment connects the laboratory result to symptoms such as reduced sexual desire, fewer spontaneous erections, anemia, low bone density, or unexplained loss of body hair, and to alternative explanations. Sleep disorders, depression, medication effects, obesity, systemic illness, and alcohol or substance use can overlap with testosterone-related symptoms. "Low energy" alone is nonspecific.

The American Urological Association also recommends using two early-morning total-testosterone measurements for diagnosis. It emphasizes a documented clinical picture rather than treatment from one value. If results conflict or an assay is questionable, repeating testing through a reliable laboratory can be more informative than ordering a large set of unvalidated add-ons.

Before starting or changing therapy

Testosterone treatment is a clinical decision, not the automatic endpoint of a low lab. The Endocrine Society lists several situations in which clinicians should avoid starting treatment, including people planning fertility in the near term and certain prostate, breast, cardiovascular, or hematologic circumstances. The baseline and follow-up plan must be individualized to the formulation and the patient's risks.

Bring a medication list, supplements, sleep history, fertility goals, and prior hormone results. Ask which assay was used, whether the sample timing was appropriate, and what specific diagnosis the extra tests are intended to clarify. That produces a more reliable answer than chasing a "normal" free-testosterone number.

What each paired result can and cannot answer

Timing and laboratory consistency

Use the same laboratory and assay when practical for a confirmatory test. Switching platforms can create an apparent change that is mostly analytical rather than biological. Record the collection time, sleep disruption, acute illness, fasting status if instructed, recent strenuous exercise, and any medication changes. These details let the clinician decide whether a result is interpretable or should simply be repeated.

Reference ranges describe a laboratory population; they do not create a treatment target for every age or symptom pattern. The useful question is whether the result is consistently low by a reliable method and whether it fits the clinical picture. In people taking exogenous testosterone, the sampling time relative to the formulation also matters. A trough for an injection and a result after a topical application answer different questions, so the treating clinician should specify timing before the blood draw.

Fertility, estradiol, and safety monitoring

For a person trying to conceive, testosterone results should trigger a fertility discussion before any treatment decision. Exogenous testosterone can suppress gonadotropins and sperm production. LH/FSH, semen analysis, reproductive history, and referral may be more informative than trying a supplement. Estradiol testing is similarly context-dependent: it may be relevant for certain symptoms or therapy monitoring, but it is not a universal explanation for low energy or body-composition goals.

The baseline safety discussion differs from diagnostic testing. A clinician considering testosterone therapy may evaluate hematocrit, prostate-related history and testing when appropriate, cardiovascular history, sleep apnea risk, and contraindications. This page is not a mandate to order every laboratory test. It is a map for asking why each test is being ordered and how its result will change the next decision.